TherapeuticsMD to Present at Two Upcoming Investor Conferences

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced that the company will participate in two
upcoming investor conferences.

Chief Executive Officer Robert G. Finizio will provide an overview of
the company at the Jefferies 2016 Health Care Conference in New York on
Tuesday, June 7. Chief Clinical Officer Brian Bernick, M.D., will
participate in the Goldman Sachs 37th Annual Global Healthcare
Conference in Rancho Palos Verdes, California on Thursday, June 9.

Both presentations will be webcast live and an archive will be available
on the company’s website. Details for the two presentations are as
follows:

       
Conference     Jefferies Securities Annual Health Care Conference
Date     Tuesday, June 7, 2016
Time     2:00 p.m. ET
Live Webcast    

http://wsw.com/webcast/jeff97/txmd

   
       
Conference     Goldman Sachs 37th Annual Health Care Conference
Date     Thursday, June 9, 2016
Time     10:00 a.m. PT
Live Webcast    

https://cc.talkpoint.com/gold006/060716b_ae/?entity=95_EN8VX4V

 

The webcast replays will be available for at least 30 days following the
conferences on the company’s website,
www.therapeuticsmd.com
, in the “Investors & Media” section.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD®
brands.

Forward Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of
the company’s clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; the company’s reliance on third parties
to conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website:
www.therapeuticsmd.com/pressreleases.aspx.

Contacts

TherapeuticsMD, Inc.
David Delucia, 561-961-1900 (ext. 2010)
Director
of Investor Relations
David.Delucia@TherapeuticsMD.com